List of Excipients in Branded Drug PANDEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
PharmaDerm a division of Fougera Pharmaceuticals Inc	PANDEL	hydrocortisone probutate	10337-153	ANHYDROUS TRISODIUM CITRATE
PharmaDerm a division of Fougera Pharmaceuticals Inc	PANDEL	hydrocortisone probutate	10337-153	BUTYLPARABEN
PharmaDerm a division of Fougera Pharmaceuticals Inc	PANDEL	hydrocortisone probutate	10337-153	CITRIC ACID MONOHYDRATE
PharmaDerm a division of Fougera Pharmaceuticals Inc	PANDEL	hydrocortisone probutate	10337-153	GLYCERYL MONOSTEARATE
PharmaDerm a division of Fougera Pharmaceuticals Inc	PANDEL	hydrocortisone probutate	10337-153	GLYCERYL STEARATE SE
PharmaDerm a division of Fougera Pharmaceuticals Inc	PANDEL	hydrocortisone probutate	10337-153	LIGHT MINERAL OIL

PANDEL Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Pandel is a topical desonide product positioned in the low-potency corticosteroid segment. Its commercial value is driven less by active-ingredient exclusivity and more by vehicle performance, tolerability, packaging, patient adherence, and efficient generic or differentiated-product development. The strongest opportunities are a therapeutically equivalent lotion, a lower-irritancy formulation, pediatric-focused packaging, and potentially new topical presentations such as foam, gel, spray, or emulsion.

What is Pandel and how is it positioned commercially?

Pandel contains desonide, a low-potency topical corticosteroid used for corticosteroid-responsive dermatoses. The product is applied topically and is generally positioned for inflammatory skin conditions where a lower-potency steroid is appropriate, including certain pediatric or facial-use situations under medical supervision (U.S. Food and Drug Administration [FDA], Pandel prescribing information).

The key commercial characteristics are:

Attribute	Pandel
Active ingredient	Desonide
Therapeutic class	Low-potency topical corticosteroid
Dosage form	Lotion
Regulatory status	Prescription drug
Primary value drivers	Vehicle feel, spreadability, cosmetic acceptability, tolerability, adherence
Biosimilar exposure	None
Generic pathway	Abbreviated New Drug Application, subject to product-specific requirements
Patent relevance	Primarily formulation, delivery, packaging, and use patents rather than active-ingredient patents
Main competitors	Generic desonide creams, ointments, lotions, gels, foams, and other low-potency corticosteroids

Pandel competes with generic desonide products and other low-potency topical steroids, including hydrocortisone, alclometasone, and fluocinolone acetonide products. The prescribing decision often depends on potency, dosage form, anatomical site, age, payer coverage, and vehicle acceptability rather than active ingredient alone.

What excipients are used in Pandel lotion?

The Pandel label identifies a conventional topical lotion base containing fatty alcohols, humectants, emollients, surfactants, a polymeric thickener, preservative, pH-adjusting agent, and purified water. The specific inactive-ingredient profile listed in U.S. labeling includes components such as cetyl alcohol, stearyl alcohol, glycerin, glyceryl stearate, isopropyl myristate, polysorbate 20, propylene glycol, methylparaben, carbomer, sodium hydroxide, and purified water, subject to the applicable label version (FDA, Pandel prescribing information).

The excipient functions are commercially relevant:

Excipient category	Likely function in Pandel lotion	Development implications
Purified water	Continuous phase	Microbial control and preservative performance
Glycerin	Humectant	Hydration and skin feel; excessive levels may increase tack
Propylene glycol	Humectant, solvent, penetration and preservation aid	Can cause irritation or allergic contact dermatitis in susceptible patients
Cetyl and stearyl alcohol	Structuring agents and emollients	Improve viscosity, glide, and film formation
Glyceryl stearate	Emulsifier and emollient	Supports oil-in-water emulsion structure
Isopropyl myristate	Emollient and spreadability enhancer	May improve feel but can affect irritation, occlusion, and stability
Polysorbate 20	Surfactant and solubilizer	Can influence emulsion stability and sensory properties
Carbomer	Rheology modifier	Controls viscosity, suspension, and application behavior
Methylparaben	Preservative	Requires compatibility assessment and regulatory labeling review
Sodium hydroxide	Neutralizer and pH adjuster	Controls carbomer hydration and final pH

The formulation is a conventional emulsion rather than a highly specialized delivery system. That creates development flexibility but also makes vehicle differentiation difficult to protect through broad composition claims.

How should a generic manufacturer approach Pandel excipient selection?

A generic Pandel strategy should prioritize pharmaceutical equivalence, topical performance, stability, and manufacturability. The target is not simply to reproduce the ingredient list. The formulation must deliver comparable quality attributes and support the regulatory evidence required for the proposed dosage form.

Priority 1: Match the lotion's physical performance

The development target should include:

• Appearance and color
• pH
• Viscosity and rheology profile
• Droplet-size distribution
• Spreadability
• Drying time
• Residue and tack
• Phase separation resistance
• Redispersibility, if relevant
• Drug content uniformity
• In-vitro release rate
• Microbial limits and preservative effectiveness

For topical products, Q1 sameness and Q2 similarity can reduce regulatory risk, but qualitative and quantitative excipient matching does not by itself guarantee equivalent performance. FDA's topical-product guidance places substantial emphasis on product quality, formulation composition, manufacturing controls, and performance testing (FDA, 2022).

Priority 2: Manage irritation and sensitization risk

Propylene glycol and preservatives can create differentiation opportunities. A manufacturer could evaluate:

• Lower propylene glycol concentration
• Alternative humectants such as butylene glycol, pentylene glycol, or sorbitol
• Alternative preservatives
• Reduced surfactant load
• Fragrance-free positioning
• Lower residual solvent profile
• Improved pH control
• Reduced alcohol content

Any substitution must preserve desonide solubility, emulsion stability, microbiological quality, release characteristics, and shelf life. A lower-irritancy claim would require clinical or well-designed tolerability support and could not be inferred solely from excipient substitution.

Priority 3: Improve patient handling

Lotion dosage forms can be difficult to dispense accurately and may run on vertical or inflamed skin. Potential improvements include:

• Pump delivery instead of a squeeze tube
• Metered-dose dispensing
• Airless packaging
• Narrow-orifice tubes
• Unit-dose sachets for samples or institutional use
• Packaging designed for pediatric caregiver use
• Tamper-evident closure systems
• Container compatibility testing with the emulsion

Packaging patents may offer stronger commercial protection than broad excipient patents when they solve a defined dosing or stability problem.

What formulation patents could protect a Pandel follow-on product?

The strongest patent opportunities are likely to involve a defined technical effect rather than a simple list of excipients.

Excipient-composition patents

A patent could claim a desonide lotion containing specified ranges of:

• Desonide
• Humectant
• Emollient
• Emulsifier
• Rheology modifier
• Preservative
• pH-adjusting agent
• Water

Broad composition claims would face substantial prior-art risk because topical corticosteroid emulsions and lotions are well developed. Narrower claims could focus on a particular concentration range that produces improved stability, lower irritation, faster drying, or a specific release profile.

Vehicle and delivery patents

Potentially stronger claim themes include:

• A non-greasy lotion with defined drying time
• A low-irritancy desonide emulsion
• A formulation with improved desonide release
• A pump-delivered lotion with dose uniformity
• A formulation with enhanced skin deposition and reduced systemic exposure
• A preservative-reduced or preservative-free system
• A sprayable emulsion for large-area application

The patent must link the claimed composition to a measurable technical benefit. A claim that merely substitutes one common emollient for another may face obviousness challenges.

Manufacturing-process patents

Manufacturing protection could cover:

• Order of addition
• Homogenization conditions
• Temperature profile
• Carbomer neutralization
• Desonide dissolution or dispersion
• Deaeration
• Filling conditions
• Control of droplet size and viscosity

Process claims can protect manufacturing know-how even when composition claims are narrow. Their commercial value depends on whether competitors can reach the same product quality through a different process.

Method-of-use patents

A method-of-use patent could target:

• A defined treatment regimen
• A specific anatomical site
• A pediatric population
• A reduced-frequency application schedule
• Treatment of a specified inflammatory dermatosis
• Improved tolerability through a particular vehicle

Method-of-use protection is generally more vulnerable when the underlying use of desonide for inflammatory skin disease is already established. A narrow, clinically supported regimen would have greater value than a broad claim to treating corticosteroid-responsive dermatoses.

When does Pandel lose exclusivity?

Pandel's commercial exclusivity is likely limited because desonide is an established corticosteroid and generic desonide products are available. The main exclusivity question is not the age of desonide but whether any current, enforceable product-specific patents or regulatory exclusivities protect the Pandel product or a particular dosage form.

Exclusivity layer	Relevance to Pandel
Active-ingredient patent	Low relevance; desonide is an established molecule
New-drug exclusivity	Likely expired for the underlying active ingredient
Formulation patent	Potentially relevant if listed and enforceable
Method-of-use patent	Potentially relevant, but scope must be assessed claim by claim
Packaging patent	Relevant to a differentiated product, usually not a barrier to all generic products
Orange Book listing	Must be verified against the current FDA Orange Book
State or federal trademark rights	May protect the Pandel name, not the underlying formulation
Biosimilar exclusivity	Not applicable

The FDA Orange Book should be checked for any currently listed patents associated with the relevant Pandel reference product. A patent listed against one dosage form does not necessarily block products in other dosage forms. A formulation patent may also be vulnerable to a Paragraph IV certification if an ANDA applicant asserts that the patent is invalid, unenforceable, or not infringed (FDA, Orange Book).

What Paragraph IV and generic-entry risks affect Pandel?

Generic-entry risk is high at the molecule level and moderate at the product level. Desonide has a long commercial history, and generic manufacturers can compete through creams, ointments, lotions, gels, and other approved presentations.

A potential ANDA applicant would typically assess:

1. The reference-listed drug designation.
2. The applicable FDA product-specific guidance.
3. Pharmaceutical equivalence requirements.
4. In-vitro release testing.
5. Comparative physicochemical characterization.
6. Any required clinical endpoint or pharmacodynamic study.
7. Orange Book patents.
8. Paragraph IV certification exposure.
9. Labeling differences and carve-outs.
10. Manufacturing-site and supply-chain readiness.

A Paragraph IV challenge would be commercially meaningful only if a listed patent creates a real launch delay. If no enforceable patent remains, a generic applicant could pursue approval based on the applicable ANDA pathway and launch subject to regulatory approval, manufacturing readiness, and commercial strategy.

What is the FDA regulatory status of Pandel?

Pandel is a prescription topical corticosteroid, not a biologic. It therefore does not face biosimilar competition. Competitors would generally use the ANDA pathway for a therapeutically equivalent product, although the evidentiary requirements depend on the exact dosage form and FDA guidance.

The main regulatory risks are:

• Failure to demonstrate equivalent product quality
• Inadequate preservative effectiveness
• Inconsistent viscosity or droplet size
• Poor container-closure compatibility
• Inadequate in-vitro release performance
• Labeling differences
• Uncontrolled microbial contamination
• Excipient changes that alter absorption or local tolerability

For a novel dosage form, such as foam or spray, a 505(b)(2) application may be more appropriate than an ANDA if no suitable reference product exists or if the proposed product relies on new clinical or delivery-system data.

Which commercial opportunities exist beyond a conventional Pandel generic?

Lower-irritancy desonide lotion

A formulation with reduced propylene glycol, an alternative preservative system, and improved pH control could target patients with sensitive or compromised skin. The opportunity would require comparative tolerability testing.

Pediatric and caregiver-oriented packaging

Desonide's low potency supports a pediatric-focused commercial strategy, although safety remains dependent on application site, duration, amount, and medical supervision. A metered pump or dose-control package could improve adherence and reduce overapplication.

Large-area application

A sprayable emulsion or light lotion could improve use on the scalp, trunk, or larger affected areas. The product would need to control spray inhalation, flammability if alcohol is used, dosing uniformity, and local tolerability.

Cosmetic acceptability

A fast-drying, low-residue formulation could compete with greasy creams and ointments. This positioning is commercially relevant for visible areas and workday use, but it must be supported by validated sensory or patient-preference data.

Institutional and payer contracts

A generic lotion with stable supply, competitive pricing, and a differentiated package could target dermatology clinics, pediatric practices, hospital formularies, and managed-care contracts. In this segment, manufacturing reliability and acquisition cost can outweigh incremental vehicle improvements.

How strong is the Pandel patent estate?

The likely patent strength is weak to moderate for the underlying active ingredient and potentially stronger for narrowly defined improvements. A commercial assessment should separate four questions:

Question	Strategic assessment
Is desonide itself protected?	Unlikely to be the primary barrier
Is the Pandel lotion formulation protected?	Requires current Orange Book and patent-record review
Can a competitor design around the vehicle?	Usually yes, unless claims are broad and technically difficult to avoid
Can packaging or process patents delay entry?	Possible, but usually limited to the protected implementation

The most durable protection would combine a formulation claim, a manufacturing process claim, and a package or delivery claim supported by comparative performance data. A single broad excipient claim is less likely to withstand invalidity and design-around pressure in a mature topical market.

What licensing and partnering opportunities exist?

Potential deal structures include:

• Licensing a proprietary topical emulsion platform
• Co-development with a dermatology-focused manufacturer
• Regional licensing of a generic desonide product
• Contract manufacturing with formulation transfer
• Authorized-generic supply arrangements
• Licensing of metered-dose topical packaging
• Acquisition of a 505(b)(2) topical delivery platform

The best licensing asset would have a clear technical advantage, freedom-to-operate position, scalable manufacturing process, and evidence of improved adherence or tolerability. A conventional excipient substitution without differentiated clinical or commercial performance would have limited licensing value.

What generic launch scenarios are most likely?

Scenario 1: Conventional lotion generic

This is the highest-probability scenario. The competitor matches the reference dosage form and seeks approval through the standard generic pathway. Price competition would be immediate if multiple approved products enter.

Scenario 2: Low-cost desonide dosage-form expansion

A manufacturer could use an existing desonide platform to launch a cream, ointment, gel, or foam. This would expand competition but would not necessarily substitute directly for Pandel lotion.

Scenario 3: Differentiated 505(b)(2) product

A novel pump, spray, foam, or low-irritancy vehicle could support premium pricing if the sponsor demonstrates a meaningful clinical or usability advantage.

Scenario 4: Authorized generic or branded-generic strategy

A branded manufacturer could preserve distribution and payer access through an authorized generic, co-branded product, or contract-supplied equivalent. This strategy would depend on manufacturing economics and channel relationships.

Key Takeaways

• Pandel is a prescription desonide lotion whose commercial differentiation depends primarily on vehicle performance and patient usability.
• Desonide's molecule-level patent value is limited because it is an established active ingredient.
• The principal excipient opportunities are lower irritation, better spreadability, faster drying, improved preservation, and more precise dispensing.
• Broad excipient patents are likely to face prior-art and obviousness challenges.
• Packaging, manufacturing-process, and defined-performance claims may provide stronger practical protection.
• Generic competition is the principal commercial risk; biosimilar competition is not relevant.
• A conventional ANDA generic is the most direct opportunity.
• A 505(b)(2) product could support greater differentiation through a new dosage form or delivery system.
• Current Orange Book listings, patent ownership, litigation, and settlement status must be evaluated against the specific reference-listed Pandel product and current FDA records before investment or launch decisions.

FAQs About Pandel Excipient and Commercial Strategy

Can Pandel be reformulated without propylene glycol?

Yes, but the reformulation must preserve desonide solubility or dispersion, emulsion stability, microbiological quality, skin feel, in-vitro release, and shelf life. Propylene glycol removal may reduce irritation for some users but can create new stability and preservation problems.

Is a Pandel lotion generic easier to develop than a desonide foam?

Usually. A lotion closer to the reference product can use established formulation and performance methods. A foam may require additional work on propellant or foaming systems, container compatibility, dose delivery, flammability, and comparative clinical performance.

Can an excipient change create a new patent for desonide?

Yes, but the patent must claim a novel and non-obvious composition, process, delivery system, or technical effect. A routine substitution of a commonly used excipient is unlikely to provide strong protection by itself.

Does Pandel have biosimilar risk?

No. Pandel contains desonide, a small-molecule corticosteroid. Competitive products are generics or other topical drug products, not biosimilars.

What is the highest-value commercial improvement for Pandel?

A metered, low-residue, low-irritancy lotion with reproducible dosing would have the strongest combination of patient, payer, and intellectual-property value, provided the sponsor can demonstrate equivalent or improved performance and obtain suitable regulatory protection.

References

1. U.S. Food and Drug Administration. (n.d.). Pandel (desonide) lotion prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs: Draft guidance for industry. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2016). Guidance for industry: ANDAs for certain highly purified synthetic peptides. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. U.S. Department of Health and Human Services.